What Dose Did Your Patients Receive?
What is Preventing You from Knowing?
Inadequate Information and Model Limitations
Current options, such as BSA, MIRD, and partition models do not correlate to actual dose delivery.
- Using BSA, 86% of patients did not receive the target tumor dose of > 120 Gy in a recent Journal of Nuclear Medicine study.1
- The partition model overestimates the normal liver doses by 2x, according to an International Journal of Radiation Oncology study.2
- In that same study, it was determined that MIRD Single Compartment was unable to predict tumor dose for any subset of tumor types and sizes compared to voxel-based dosimetry.2
Subsequent Treatment are Limited
Lack of confidence and knowledge of Y90 treatments limits oncologists' subsequent treatment options.
“Should we do a follow-up Y90 if there was inadequate dose delivery?”
“Should we do a follow-up external beam for better coverage?”
MIM SurePlan™ LiverY90
A Comprehensive Solutions for Y90
MIM SurePlan LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT.
Know Your Dose the Day of Treatment
Patient-specific dosimetry overcomes the uncertainty that the existing planning methods do not correlate with the actual dose delivered.
Empower Your Oncologists
With patient-specific dosimetry, referrers have increased confidence that Y90 is a more legitimate treatment option. Make the best treatment path available to your patient by opening up subsequent treatment options using the knowledge gained.
Timesaving Tools
MIM SurePlan LiverY90 is specifically engineered for Y90, making efficiency a top priority. A recent study3 in the Journal of Nuclear Medicine demonstrated a 70% reduction in time compared to manual outlining of the liver.
Post-Op Dosimetry
Calculate dose using Y90-PET and Bremsstrahlung SPECT. Calculate isodose curves/DVH on PET/SPECT using Local Disposition Method or MIRD Kernal.
Additional Resources
See How Experts are Using MIM SurePlan LiverY90 in the Clinic
Syllabus
Y90 Research SyllabusFind Out How MIM Can Improve Your Clinical Workflow
Schedule a Meeting
Footnotes
- Kafrouni, Marilyne, Carole Allimant, Marjolaine Fourcade, Sébastien Vauclin, Julien Delicque, Alina-Diana Ilonca, Boris Guiu, et al. “Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome.” Journal of Nuclear Medicine 59, no. 8 (2018): 1289–95. https://doi.org/10.2967/jnumed.117.202937.
- Mikell, Justin K., Armeen Mahvash, Wendy Siman, Veera Baladandayuthapani, Firas Mourtada, and S. Cheenu Kappadath. “Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.” International Journal of Radiation Oncology*Biology*Physics 96, no. 4 (2016): 888–96. https://doi.org/10.1016/j.ijrobp.2016.07.021.
- M Horvat, et al., Time Savings of a Multi-Atlas Approach for Liver Segmentation. Journal of Nuclear Medicine 55, no.1 (2014): 1523.